

ASX Announcement | 20 May 2022
Althea Group Holdings (ASX:AGH)

Althea continues European expansion with Ireland market entry

Althea CBD12:THC10 approved for prescription and supply in Republic of Ireland

Financial Highlights:

- Althea to enter the Irish medicinal cannabis market following The Health Products Regulatory Authority approval of Althea CBD12:THC10
- Althea CBD12:THC10 is one of a limited number of medicinal cannabis products approved for prescription in the Republic of Ireland
- The Company has submitted applications for additional Althea products for consideration by the Irish health regulator

20 May 2022: **Althea Group Holdings Limited (ASX:AGH) ('AGH', or 'the Company')**, a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products, is pleased to announce that the Health Products Regulatory Authority (**'HPRA'**) has approved **Althea CBD12:THC10** product for prescription and supply in the Republic Ireland.

Details

Althea is to enter the Irish medicinal cannabis market following the approval of Althea CBD12:THC10 by Ireland's medicines regulator, HPRA and the Minister for Health.

Althea CBD12:THC10 is one of a limited number of medicinal cannabis products available for prescription and supply in the Republic of Ireland. The Company is seeking further product approvals in Ireland.

An application will follow for Althea CBD12:THC10 to be added to the Primary Care Reimbursement Service in the Republic of Ireland as part of the Medicinal Cannabis Access Programme (MCAP), making it free of charge for Irish patients prescribed the treatment under the Medicinal Cannabis Access Programme.

The programme makes it possible for a medical consultant to prescribe a cannabis-based treatment for a patient under their care for the following medical conditions, where the patient has failed to respond to standard treatments:

- Spasticity associated with multiple sclerosis
- Intractable nausea and vomiting associated with chemotherapy
- Severe, refractory (treatment-resistant) epilepsy



AGH CEO, Joshua Fegan said: “The approval of our first medicinal cannabis product in the Republic of Ireland is another positive achievement aligned to our European growth strategy for Althea. Having one of only a limited number of cannabis-based medicines approved for sale in Ireland is a massive advantage for Althea and when combined with our world-class medical education program, we aim to achieve positive and sustainable growth in Ireland over the years to come.”

-ENDS-

Authorised by: Robert Meissner, Company Secretary

For further information, please contact:

Althea

Josh Fegan

CEO & Managing Director

M: 1300 70 20 20

E: info@altheagroupholdings.com

Media Enquiries

Dan Francome

Media Relations

P: +613 9650 5096

E: dfrancome@altheagroupholdings.com

Investor Relations

Madeline Howson

Client Services

P: +61 434 073 160

E: madeline.howson@advisir.com.au

Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd ('AGH') is a global leader in the manufacturing, sales and distribution of cannabis-based medicines and recreational cannabis products. AGH services these sectors via two distinct business units. Althea, the company's pharmaceutical business, offers a comprehensive range of cannabis-based medicines which are made available to patients via prescription. Peak Processing Solutions, AGH's recreational cannabis business, produces legal cannabis products purchased by adult consumers in retail stores.

AGH operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more about Althea Group Holdings, please visit: www.altheagroupholdings.com

For more information on Peak, please visit: www.peakprocessing.com

For more information on Althea, please visit: www.althea.life

